ClinicalTrials.gg
TerminatedNCT01925950Updated Nov 1, 2018Results posted

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

A Phase 2 interventional study of orBec and Placebo in Chronic Gastrointestinal Graft vs Host Disease, sponsored by Soligenix. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-01.

Sponsored by Soligenix · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was stopped due to patient enrollment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
2
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
347th of 389
2 · median 30
Started
2013
with 18 others
Phase 2
164 of 454
15 open now
Registered
255th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 347th largest by enrollment of the 389 interventional ones that give a count, is one of 19 that started in 2013, is one of 164 in phase 2, and was the 255th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

Use of an oral topically-active glucocorticoid with limited side effects may control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.

03

Conditions studied

  • Chronic Gastrointestinal Graft vs Host Disease

Browse trials for

Keywords

  • BDP
  • orBec
  • GVHD
  • beclomethasone dipropionate
  • bone marrow transplant
  • hematopoietic cell transplant
  • HCT
  • stem cell transplant
  • marrow transplant
  • SCT
  • beclomethasone 17,21-dipropionate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receipt of hematopoietic cell transplant >100 days prior to consent
  • Documented cGVHD as defined by the NIH consensus criteria in at least one organ system other than the GI tract (for example, cGVHD of the oral cavity would qualify as a criterion)
  • Endoscopic findings consistent with GI
  • Must be able to swallow tablets
  • Must be able to read and understand
  • Adequate methods for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • >500 mL/day of diarrhea on any 1 day within 3 days prior to the first dose of study drug
  • GI infection
  • Multi-organ failure or other condition that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
  • seropositivity
  • Pregnant or nursing female
  • Use of any drug to treat chronic within 28 days of the first dose of study drug
  • Evidence of recurrent or progressing malignant disorder that was the indication for HCT
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Control

    Drug: Placebo

  • Experimental
    orBec

    Investigational drug

    Drug: orBec

Interventions

  • DrugorBec

    Also known as: oral BDP, oral beclomethasone 17,21-dipropionate

  • DrugPlacebo
06

What researchers measure

Primary outcomes

  1. Gastrointestinal (GI) Graft-vs-Host Disease (GVHD) Symptoms

    Patients who achieved a Complete Response (CR) of their GI GVHD Symptoms during the Part 1, 16 week treatment period and who remained a CR at the end of the 16 week treatment period were to be eligible to continue into Part 2 of the study. All others were to discontinue. GI GVHD was assessed using a composite score based on the symptoms of satiety, nausea/vomiting, and anorexia. Each symptom was scored on a scale of 0-3, such that the minimum score = 0 and the maximum score = 9. At entry, all subjects must have a score of ≥ 3. A CR will be defined as a composite score of 0.

    Time frame: 16 weeks

07

Results

Posted Oct 4, 2018

Participant flow

Part 1
Participant flow — Part 1
MilestonePlaceboorBec
Started11
Completed11
Not completed00
Part 2
Participant flow — Part 2
MilestonePlaceboorBec
Started10
Completed00
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryGastrointestinal (GI) Graft-vs-Host Disease (GVHD) Symptoms

Patients who achieved a Complete Response (CR) of their GI GVHD Symptoms during the Part 1, 16 week treatment period and who remained a CR at the end of the 16 week treatment period were to be eligible to continue into Part 2 of the study. All others were to discontinue. GI GVHD was assessed using a composite score based on the symptoms of satiety, nausea/vomiting, and anorexia. Each symptom was scored on a scale of 0-3, such that the minimum score = 0 and the maximum score = 9. At entry, all subjects must have a score of ≥ 3. A CR will be defined as a composite score of 0.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Gastrointestinal (GI) Graft-vs-Host Disease (GVHD) Symptoms
ParticipantsPlaceboorBec
Gastrointestinal (GI) Graft-vs-Host Disease (GVHD) Symptoms10

Adverse events

Collected over 48-week study period. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/1 (100%)0/1 (0%)
orBec—0/1 (0%)0/1 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboorBec
biliary stricturesHepatobiliary disorders1/10/1
fungal pneumoniaInfections and infestations1/10/1
shortness of breathRespiratory, thoracic and mediastinal disorders1/10/1
pulmonary emboliVascular disorders1/10/1
intractable painGeneral disorders1/10/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PlaceboorBecTotal
<=18 years000
Between 18 and 65 years101
>=65 years011
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboorBecTotal
Female101
Male011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboorBecTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White112
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)PlaceboorBecTotal
United States112
08

Study locations

3 sites
  • John Theurer Cancer Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Vanderbilt-Ingram Cancer Center
    Nashville, Tennessee 37232, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 3 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2013
First posted
Aug 20, 2013
Start
Dec 2013
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Oct 4, 2018
Last update
Nov 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01925950
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
Aug 20, 2013
Start date
Dec 2013
Primary completion
May 2015
Completion
May 2015
Results posted
Oct 4, 2018
Last update
Nov 1, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion